Associations of SNP rs_7927894 of FLG gene and TARC/CCL17 with atopic dermatitis in children

Authors

  • V.O. Dityatkovsky Dnipro State Medical University, Ukraine, Ukraine https://orcid.org/0000-0002-8508-5562
  • V.O. Dityatkovsky Dnipro State Medical University, Ukraine, Ukraine https://orcid.org/0000-0001-6291-5386
  • N.V. Naumenko Dnipro State Medical University, Ukraine, Ukraine
  • O.O. Alifirenko Allergy Center of KNE «Clinical Ambulance Hospital of the Dnipro City Council», Ukraine, Ukraine
  • N.L. Pinaeva Allergy Center of KNE «Clinical Ambulance Hospital of the Dnipro City Council», Ukraine, Ukraine
  • S.M. Taran Allergy Center of KNE «Clinical Ambulance Hospital of the Dnipro City Council», Ukraine, Ukraine
  • І.А. Filatova Allergy Center of KNE «Clinical Ambulance Hospital of the Dnipro City Council», Ukraine, Ukraine

DOI:

https://doi.org/10.15574/SP.2021.118.12

Keywords:

atopic dermatitis, children, associations, polymorphism, filaggrin, thymus- and activation regulated chemokine

Abstract

One of the main genetic factors of the development of atopic dermatitis (AD) in children are single nucleotide polymorphisms (SNP) of the filagrin gene (FLG), particularly rs_7927894 FLG. One of the mostly studied and promising AD marker chemokines (CK) is the thymusE and activation regulated chemokine (TARC/CCL17).

Purpose – to detect the associations and role of different variants of SNP rs_7927894 FLG gene and TARC/CCL17 in children suffering different AD clinical proE files (CP) – isolated or combined with comorbid atopic disorders (AtD).

Materials and methods. The main group comprised 39 patients aged 3 to 18 years, suffering the isolated AD or combined with comorbid AtD. The control group comprised 47 patients aged 3 to 18 years, suffering the pathology of gastrointestinal tract without clinical signs of atopy. All the patients of the main and control groups had undergone detection of the genotype variants of SNP rs_7927894 FLG gene by real-time polymerase chain reaction and detection of TARC/CCL17 serum concentrations in venous blood. The cutEoff value of statistical significance was set as p<0.05.

Results. The incidence and association of genotype variants C/C, C/T and T/T SNP rs_7927894 FLG gene in patients of cohorts of the studied groups were detected as follows: C/T rs_7927894 FLG was significantly the most common in the general main group (56.4%, p<0.05), within the cohort of CP AD isolated (61.1%, p<0.05) and CP of AD combined with comorbid AtD (52.4%, p<0.05). There were detected the associations of studied SNP with AD: C/T rs_7927894 FLG is significantly directly associated with AD (r=0.291, p<0.05), C/C rs_7927894 FLG has a reverse association with a trend to significance (r=-0.194, p=0.07). Mean serum concentrations of TARC/CCL17 did not differ significantly among patients cohorts of the main and control groups, respectively: general main group — 615.8 pg/ml, main with a CP AD isolated — 651.3 pg/ml, main with a CP of AD combined with comorbid AtD — 585.4 pg/ml, control — 608.4 pg/ml (p>0.05). Associations of serum TARC/CCL17 concentrations were determined as follows: elevation trending to significance within increasing AD severity degree (r=0.290, p=0.07) and significant elevation within the AD exhacerbation period (r=0.426, p<0.05). No significant association of TARC/CCL17 as to AD patients compared to the control group was detected in our study (r=-0.027, p>0.05).

Conclusions. The genotype heterozygote variant C/T rs_7927894 FLG is significantly the most common and associated with all AD CP in children — isolated and combined with comorbid AtD. Variant C/C rs_7927894 of FLG gene is significantly reversely associated with AD in children. Serum concentrations of TARC/CCL17 did not reveal any significant differences between the AD patients and nonEatopic ones. However, they significantly elevate within AD exacerbation phase and trending to significance within AD severity degree increase in children.

The research was carried out in accordance with the principles of the Helsinki declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies.

No conflict of interest was declared by the authors.

References

Armengot-Carbo M, Hernandez-Martin A, Torrelo A. (2015, Mar). The role of filaggrin in the skin barrier and disease development. Actas Dermosifiliogr. 106 (2): 86-95. English, Spanish. Epub 2014 Mar 24. https://doi.org/10.1016/j.ad.2013.10.019; PMid:24674607

Cepelak I, Dodig S, Pavic I. (2019). Filaggrin and atopic march. Biochem Med (Zagreb). 29 (2): 020501. https://doi.org/10.11613/BM.2019.020501; PMid:31223255 PMCid:PMC6559618

Debinska A, Danielewicz H, Drabik-Chamerska A, Kalita D, Boznanski A. (2020). Chromosome 11q13.5 variant as a risk factor for atopic dermatitis in children. Postepy Dermatol Alergol. 37 (1): 103-110. https://doi.org/10.5114/ada.2020.93388; PMid:32467693 PMCid:PMC7247065

Esaki H, Takeuchi S, Furusyo N, Yamamura K, Hayashida S, Tsuji G et al. (2016, Nov). Levels of immunoglobulin E specific to the major food allergen and chemokine (C-C motif) ligand (CCL) 17/thymus and activation regulated chemokine and CCL 22/macrophage-derived chemokine in infantile atopic dermatitis on Ishigaki Island. J Dermatol. 43 (11): 1278-1282. Epub 2016 Mar 30. https://doi.org/10.1111/1346-8138.13360; PMid:27028543

Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K et al. (2009, Nov). Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol. 20 (7): 633-641. Epub 2009 Feb 11. https://doi.org/10.1111/j.1399-3038.2009.00851.x; PMid:19236603

Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H et al. (2001). Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 107: 535-541. https://doi.org/10.1067/mai.2001.113237; PMid:11240957

Kataoka Y. (2014, Mar). Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 41 (3): 221-229. https://doi.org/10.1111/1346-8138.12440; PMid:24628072

Machura E, Rusek-Zychma M, Jachimowicz M, Wrzask M, Mazur B, Kasperska-Zajac A. (2012, May). Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. Pediatr Allergy Immunol. 23 (3): 278-284. Epub 2011 Oct 21. https://doi.org/10.1111/j.1399-3038.2011.01225.x; PMid:22017510

Miyahara H, Okazaki N, Nagakura T, Korematsu S, Izumi T. (2011, Feb). Elevated umbilical cord serum TARC/CCL17 levels predict the development of atopic dermatitis in infancy. Clin Exp Allergy. 41 (2): 186-191. Epub 2010 Nov 5. https://doi.org/10.1111/j.1365-2222.2010.03634.x; PMid:21054588

Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N. (2008, Nov). Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol. 19 (7): 605-613. Epub 2008 Feb 6. https://doi.org/10.1111/j.1399-3038.2007.00692.x; PMid:18266834

Poninska JK, Samolinski B, Tomaszewska A, Raciborski F, Samel-Kowalik P, Walkiewicz A et al. (2017, Sep 8). Haplotype dependent association of rs7927894 (11q13.5) with atopic dermatitis and chronic allergic rhinitis: A study in ECAP cohort. PLoS One. 12 (9): e0183922. https://doi.org/10.1371/journal.pone.0183922; PMid:28886043 PMCid:PMC5590850

Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C et al. (2015, Oct). Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 15 (5): 453-460. https://doi.org/10.1097/ACI.0000000000000198; PMid:26226355

Umeda M, Origuchi T, Kawashiri SY, Koga T, Ichinose K, Furukawa K et al. (2020). Thymus and Activation-regulated Chemokine as a Biomarker for IgG4-related Disease. Sci Rep. 10 (1): 6010. https://doi.org/10.1038/s41598-020-62941-9; PMid:32265499 PMCid:PMC7138842

Vestergaard C. (2007). TARC and CTACK. Two Pivotal Chemokines in Atopic Dermatitis. Forum Nordic Derm-Venear. 14 (12): 37.

Zhao X, Delgado L, Weiner R, Laterza OF. (2014, Apr). An ultra-sensitive clinical biomarker assay: quantitation of thymus and activation-regulated chemokine in human plasma. Bioanalysis. 6 (8): 1069-1080. https://doi.org/10.4155/bio.14.72; PMid:24830891

Published

2021-10-29

Issue

Section

Original articles